Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyFenbufen
Identification
- Name
- Fenbufen
- Accession Number
- DB08981
- Type
- Small Molecule
- Groups
- Approved
- Description
Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.
- Structure
Structure for DB08981 (Fenbufen)
- Synonyms
- 3-(4-Biphenylylcarbonyl)propionic acid
- 3-(4-Phenylbenzoyl)propionic acid
- 4-(4-Biphenylyl)-4-oxobutyric acid
- 4-Biphenyl-4-yl-4-oxobutanoic acid
- Fenbufen
- gamma-oxo(1,1'-Biphenyl)-4-butanoic acid
- External IDs
- CL 82,204
- Categories
- Acids, Carbocyclic
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Central Nervous System Agents
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Musculo-Skeletal System
- Peripheral Nervous System Agents
- Propionates
- Sensory System Agents
- UNII
- 9815R1WR9B
- CAS number
- 36330-85-5
- Weight
- Average: 254.2806
Monoisotopic: 254.094294314 - Chemical Formula
- C16H14O3
- InChI Key
- ZPAKPRAICRBAOD-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
- IUPAC Name
- 4-oxo-4-(4-phenylphenyl)butanoic acid
- SMILES
- OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fenbufen. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Fenbufen is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Fenbufen is combined with 5-androstenedione. Experimental, Illicit Abciximab Fenbufen may increase the anticoagulant activities of Abciximab. Approved Acebutolol Fenbufen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Fenbufen may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fenbufen. Approved, Vet Approved Aclarubicin Fenbufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Fenbufen. Approved Alclofenac The risk or severity of adverse effects can be increased when Fenbufen is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Fenbufen is combined with Aldosterone. Experimental, Investigational Aldoxorubicin Fenbufen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Alendronic acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid. Approved Aliskiren Fenbufen may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Fenbufen is combined with Alminoprofen. Experimental Alprenolol Fenbufen may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Fenbufen. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Amcinonide. Approved Amikacin Fenbufen may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Fenbufen may decrease the antihypertensive activities of Amiloride. Approved Amrubicin Fenbufen may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Fenbufen may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Fenbufen. Investigational Androstenedione The risk or severity of adverse effects can be increased when Fenbufen is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Fenbufen is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Fenbufen is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Fenbufen is combined with Anisodamine. Investigational Annamycin Fenbufen may decrease the excretion rate of Annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Fenbufen. Approved, Investigational Antithrombin III human Fenbufen may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Fenbufen may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Fenbufen is combined with Apocynin. Investigational Apramycin Fenbufen may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Fenbufen. Approved, Investigational Arbekacin Fenbufen may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Fenbufen may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Fenbufen may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Fenbufen may decrease the antihypertensive activities of Arotinolol. Investigational Atamestane The risk or severity of adverse effects can be increased when Fenbufen is combined with Atamestane. Investigational Atenolol Fenbufen may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Fenbufen. Approved Azficel-T The risk or severity of adverse effects can be increased when Fenbufen is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenbufen. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Fenbufen. Investigational Balsalazide Fenbufen may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Fenbufen may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Fenbufen is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Fenbufen may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Fenbufen may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Fenbufen is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Fenbufen is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenbufen. Approved Benorilate The risk or severity of adverse effects can be increased when Fenbufen is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fenbufen. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Fenbufen is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Fenbufen. Investigational Betamethasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Betamethasone. Approved, Vet Approved Betaxolol Fenbufen may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Fenbufen. Approved, Investigational Bevantolol Fenbufen may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Fenbufen is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenbufen. Approved, Investigational Bisoprolol Fenbufen may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Fenbufen may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Fenbufen may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Fenbufen. Approved Bucillamine The risk or severity of adverse effects can be increased when Fenbufen is combined with Bucillamine. Investigational Bucindolol Fenbufen may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Fenbufen is combined with Bufexamac. Approved, Experimental Bufuralol Fenbufen may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Fenbufen is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Fenbufen. Approved Bupranolol Fenbufen may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Fenbufen. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fenbufen. Approved Candoxatril The risk or severity of adverse effects can be increased when Fenbufen is combined with Candoxatril. Experimental Captopril The risk or severity of adverse effects can be increased when Fenbufen is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Fenbufen is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenbufen. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Fenbufen. Approved, Vet Approved, Withdrawn Carteolol Fenbufen may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Fenbufen may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Fenbufen. Experimental Celecoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Celecoxib. Approved, Investigational Celiprolol Fenbufen may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Fenbufen may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Fenbufen. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenbufen. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fenbufen. Approved Ciclesonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Cilazapril. Approved Cinoxacin Fenbufen may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Citric Acid Fenbufen may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Fenbufen is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Fenbufen. Vet Approved Cloranolol Fenbufen may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Fenbufen is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Fenbufen is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Fenbufen is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Fenbufen is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fenbufen. Experimental Cyclosporine Fenbufen may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Fenbufen may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Fenbufen may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Fenbufen may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Fenbufen may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Fenbufen may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Fenbufen is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Fenbufen is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Delapril. Experimental Desirudin Fenbufen may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Fenbufen is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Fenbufen is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fenbufen. Approved, Investigational Dextran Fenbufen may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Fenbufen may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Fenbufen may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Fenbufen may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Fenbufen may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Fenbufen is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Fenbufen. Approved, Vet Approved Dicoumarol Fenbufen may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Fenbufen is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Fenbufen. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Fenbufen is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Fenbufen. Approved Dihydrostreptomycin Fenbufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Fenbufen. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fenbufen. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Fenbufen. Approved Doxorubicin Fenbufen may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Fenbufen may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Fenbufen is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Fenbufen is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Fenbufen is combined with E-6201. Investigational Edetic Acid Fenbufen may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Fenbufen may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Fenbufen is combined with Enalaprilat. Approved Enoxacin Fenbufen may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Fenbufen may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Fenbufen. Experimental Epanolol Fenbufen may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Fenbufen is combined with Epirizole. Approved Epirubicin Fenbufen may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Fenbufen. Experimental Eplerenone Fenbufen may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenbufen. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Fenbufen. Approved Equilenin The risk or severity of adverse effects can be increased when Fenbufen is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Fenbufen is combined with Equilin. Approved Esmolol Fenbufen may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenbufen. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Fenbufen. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Fenbufen is combined with Ethenzamide. Experimental Ethyl biscoumacetate Fenbufen may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Fenbufen is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Fenbufen is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Fenbufen is combined with Evening primrose oil. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Fenbufen. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Fenbufen. Experimental Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Fenbufen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Fenbufen. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fenbufen is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Fenbufen is combined with Feprazone. Experimental Ferulic acid Fenbufen may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Fenbufen. Approved, Investigational Fleroxacin Fenbufen may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Fenbufen. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Fenbufen is combined with Fludrocortisone. Approved, Investigational Fluindione Fenbufen may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Fenbufen may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Fenbufen is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Fenbufen is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Fenbufen is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Fenbufen. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Fenbufen is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fenbufen. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone propionate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenbufen. Approved, Nutraceutical, Vet Approved Fondaparinux Fenbufen may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Fenbufen may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Fenbufen. Experimental Formestane The risk or severity of adverse effects can be increased when Fenbufen is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Fenbufen is combined with Fosinopril. Approved Framycetin Fenbufen may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Fenbufen. Approved, Vet Approved Gabexate Fenbufen may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Fenbufen may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Fenbufen may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Fenbufen. Approved, Withdrawn Gemifloxacin Fenbufen may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Fenbufen may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Fenbufen may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Fenbufen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Fenbufen may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Fenbufen may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Fenbufen is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when Fenbufen is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Fenbufen is combined with HE3286. Investigational Heparin Fenbufen may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Fenbufen is combined with Higenamine. Investigational Hydralazine Fenbufen may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenbufen. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenbufen. Approved, Investigational Hygromycin B Fenbufen may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Fenbufen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Fenbufen. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Fenbufen. Approved, Investigational Idarubicin Fenbufen may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Fenbufen may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Fenbufen. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Fenbufen is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen. Approved Indenolol Fenbufen may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Fenbufen. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen. Approved, Investigational Isepamicin Fenbufen may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Fenbufen. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Fenbufen is combined with Istaroxime. Investigational Kanamycin Fenbufen may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Fenbufen. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Fenbufen. Approved Labetalol Fenbufen may decrease the antihypertensive activities of Labetalol. Approved Landiolol Fenbufen may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Fenbufen. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Fenbufen. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Fenbufen. Approved, Investigational Lepirudin Fenbufen may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Fenbufen may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Fenbufen may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Fenbufen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Fenbufen. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Fenbufen is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Fenbufen is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Fenbufen. Approved Lonazolac The risk or severity of adverse effects can be increased when Fenbufen is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fenbufen. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen. Approved Loteprednol The risk or severity of adverse effects can be increased when Fenbufen is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Fenbufen is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fenbufen. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Fenbufen. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fenbufen. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Fenbufen. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Fenbufen is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Fenbufen is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fenbufen. Approved Melagatran Fenbufen may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Fenbufen is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Fenbufen. Approved, Vet Approved Mepindolol Fenbufen may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Fenbufen may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Fenbufen. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Fenbufen may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen. Approved Metoprolol Fenbufen may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Fenbufen may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Fenbufen may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fenbufen. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenbufen. Approved Mizoribine The risk or severity of adverse effects can be increased when Fenbufen is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Fenbufen is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Fenbufen is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Fenbufen. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fenbufen. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen. Approved Nabumetone The risk or severity of adverse effects can be increased when Fenbufen is combined with Nabumetone. Approved Nadolol Fenbufen may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Fenbufen may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Fenbufen may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Fenbufen. Approved Nalidixic Acid Fenbufen may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Fenbufen. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Fenbufen is combined with NCX 1022. Investigational Neamine Fenbufen may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Fenbufen may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Fenbufen may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Fenbufen may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Fenbufen. Approved, Investigational Netilmicin Fenbufen may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Fenbufen is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fenbufen. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Fenbufen is combined with Nitroaspirin. Investigational Norfloxacin Fenbufen may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Fenbufen is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Fenbufen. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen. Approved Olsalazine Fenbufen may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Fenbufen is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Fenbufen is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Fenbufen is combined with Orgotein. Vet Approved Otamixaban Fenbufen may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fenbufen. Approved Oxolinic acid Fenbufen may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Fenbufen may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen. Approved, Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Fenbufen is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Fenbufen is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Parecoxib. Approved Paromomycin Fenbufen may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Fenbufen is combined with Parthenolide. Approved, Investigational Pazufloxacin Fenbufen may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Fenbufen may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Fenbufen may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Fenbufen may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Fenbufen may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Fenbufen is combined with Perindopril. Approved Phenindione Fenbufen may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Fenbufen may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fenbufen. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenbufen. Approved, Investigational Pindolol Fenbufen may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Fenbufen may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Fenbufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Fenbufen. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fenbufen. Approved, Investigational Piromidic acid Fenbufen may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Fenbufen. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Fenbufen is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Fenbufen is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Fenbufen may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Fenbufen may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Fenbufen may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Investigational, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenbufen. Approved Practolol Fenbufen may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Fenbufen. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Fenbufen is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Fenbufen is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Fenbufen can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Fenbufen is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Fenbufen is combined with Propacetamol. Approved, Investigational Propranolol Fenbufen may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Fenbufen is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Fenbufen is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Fenbufen. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Fenbufen. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Fenbufen. Vet Approved Protein C Fenbufen may increase the anticoagulant activities of Protein C. Approved Protein S human Fenbufen may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Fenbufen may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Fenbufen may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Fenbufen. Investigational Puromycin Fenbufen may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenbufen. Approved Ramipril The risk or severity of adverse effects can be increased when Fenbufen is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Fenbufen is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen. Approved, Experimental, Investigational Reviparin Fenbufen may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Fenbufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Fenbufen is combined with Risedronate. Approved, Investigational Rivaroxaban Fenbufen may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Fenbufen may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Fenbufen may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Fenbufen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Fenbufen. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Fenbufen. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Fenbufen. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Fenbufen. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Fenbufen. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Fenbufen. Approved, Investigational Semapimod The risk or severity of adverse effects can be increased when Fenbufen is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Fenbufen. Approved Serrapeptase The risk or severity of adverse effects can be increased when Fenbufen is combined with Serrapeptase. Investigational Sisomicin Fenbufen may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Fenbufen may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Fenbufen. Approved Sotalol Fenbufen may decrease the antihypertensive activities of Sotalol. Approved SP1049C Fenbufen may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Fenbufen may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spectinomycin Fenbufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Investigational, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Spirapril. Approved Spironolactone Fenbufen may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Fenbufen. Investigational Streptomycin Fenbufen may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Fenbufen may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenbufen. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Fenbufen. Approved, Investigational Sulodexide Fenbufen may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Fenbufen. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Fenbufen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Fenbufen is combined with Suxibuzone. Experimental Tacrolimus Fenbufen may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Fenbufen. Approved Talinolol Fenbufen may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Fenbufen. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fenbufen. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Fenbufen. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Fenbufen is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Fenbufen is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Fenbufen. Approved, Investigational Temafloxacin Fenbufen may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Fenbufen is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Fenbufen is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenbufen. Approved Tepoxalin The risk or severity of adverse effects can be increased when Fenbufen is combined with Tepoxalin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fenbufen. Approved Tertatolol Fenbufen may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fenbufen. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Fenbufen may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Fenbufen is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Fenbufen is combined with Tixocortol. Approved, Withdrawn Tobramycin Fenbufen may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Fenbufen. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Fenbufen. Approved Trandolapril The risk or severity of adverse effects can be increased when Fenbufen is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Fenbufen. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Fenbufen. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Fenbufen. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Fenbufen is combined with Triamcinolone. Approved, Vet Approved Triamterene Fenbufen may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Fenbufen is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenbufen. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Fenbufen is combined with Triptolide. Investigational Trovafloxacin Fenbufen may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Fenbufen may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Fenbufen is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Fenbufen. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Fenbufen is combined with Valdecoxib. Approved, Investigational, Withdrawn Valrubicin Fenbufen may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Fenbufen. Approved Warfarin Fenbufen may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Fenbufen may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenbufen. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Fenbufen. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Fenbufen is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Fenbufen is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Fenbufen. Withdrawn Zoptarelin doxorubicin Fenbufen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Fenbufen may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
U.S. Patent 3,784,701.
- General References
- Not Available
- External Links
- KEGG Drug
- D01344
- PubChem Compound
- 3335
- PubChem Substance
- 310264942
- ChemSpider
- 3218
- BindingDB
- 50240374
- ChEBI
- 31599
- ChEMBL
- CHEMBL277522
- PharmGKB
- PA166049176
- Wikipedia
- Fenbufen
- ATC Codes
- M01AE05 — Fenbufen
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 185-187 U.S. Patent 3,784,701. - Predicted Properties
Property Value Source Water Solubility 0.0121 mg/mL ALOGPS logP 3.07 ALOGPS logP 3 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 4.22 ChemAxon pKa (Strongest Basic) -7.5 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 54.37 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 72.49 m3·mol-1 ChemAxon Polarizability 27.47 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0f89-2900000000-b30afcea40626e90c194
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Biphenyls and derivatives / Butyrophenones / Gamma-keto acids and derivatives / Benzoyl derivatives / Aryl alkyl ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyl-phenylketone / Biphenyl / Butyrophenone / Aryl alkyl ketone / Gamma-keto acid / Benzoyl / Benzenoid / Keto acid / Monocyclic benzene moiety / Monocarboxylic acid or derivatives
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- biphenyls, 4-oxo monocarboxylic acid (CHEBI:31599)
Drug created on June 10, 2014 09:46 / Updated on March 02, 2018 03:44